title: Diagnosis and Management of Infantile Hemangioma.
abstract: Infantile hemangiomas (IHs) are the most common tumors of childhood. Unlike other tumors, they have the unique ability to involute after proliferation, often leading primary care providers to assume they will resolve without intervention or consequence. Unfortunately, a subset of IHs rapidly develop complications, resulting in pain, functional impairment, or permanent disfigurement. As a result, the primary clinician has the task of determining which lesions require early consultation with a specialist. Although several recent reviews have been published, this clinical report is the first based on input from individuals representing the many specialties involved in the treatment of IH. Its purpose is to update the pediatric community regarding recent discoveries in IH pathogenesis, treatment, and clinical associations and to provide a basis for clinical decision-making in the management of IH.
authors.forename: David H
authors.initials: DH
authors.lastname: Darrow
authors.forename: Arin K
authors.initials: AK
authors.lastname: Greene
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Mancini
authors.forename: Amy J
authors.initials: AJ
authors.lastname: Nopper
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002675:Child, Preschool; D000066491:Clinical Decision-Making; D003131:Combined Modality Therapy; D062109:Dermatologic Surgical Procedures; D018450:Disease Progression; D005260:Female; D006391:Hemangioma / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D007223:Infant; D053685:Laser Therapy; D008297:Male; D012878:Skin Neoplasms / Q000150:complications / Q000175:diagnosis / Q000628:therapy
chemical_list: D000305:Adrenal Cortex Hormones; D000319:Adrenergic beta-Antagonists